Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Bhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, Sumithira Vasu, Gregory K Behbehani, Karilyn Larkin, James S Blachly, William Blum, Rebecca B Klisovic, Amy S Ruppert, Shelley Orwick, Christopher Oakes, Parvathi Ranganathan, John C Byrd, Alison R Walker, Ramiro Garzon, Bhavana Bhatnagar, Qiuhong Zhao, Alice S Mims, Sumithira Vasu, Gregory K Behbehani, Karilyn Larkin, James S Blachly, William Blum, Rebecca B Klisovic, Amy S Ruppert, Shelley Orwick, Christopher Oakes, Parvathi Ranganathan, John C Byrd, Alison R Walker, Ramiro Garzon
Abstract
Current treatment options for older and relapsed or refractory (R/R) acute myeloid leukemia (AML) patients are limited and represent an unmet need. Based on preclinical studies showing strong anti-leukemic effects in vivo, this phase I dose-escalation study assessed the safety and preliminary clinical activity of the oral exportin-1 inhibitor, selinexor, in combination with the hypomethylating agent, decitabine 20 mg/m2, in adults with R/R AML and in older (age ≥ 60) untreated AML patients. There were no protocol-defined dose limiting toxicities. The recommended phase 2 dose of selinexor was 60 mg (∼35 mg/m2) given twice-weekly. Notable grade ≥3 toxicities included asymptomatic hyponatremia (68%), febrile neutropenia (44%), sepsis (44%), hypophosphatemia (36%), and pneumonia (28%). In 25 patients, the overall response rate was 40%. Modification of selinexor to a flat dose of 60 mg, twice-weekly for two weeks after decitabine, improved tolerability of the regimen and demonstrated preliminary clinical activity in poor-risk patients with AML.
Trial registration: ClinicalTrials.gov NCT02093403.
Keywords: Acute myeloid leukemia; clinical trials; decitabine; selinexor.
Figures
Source: PubMed